This inventor holds 1 USPTO granted patent and 3 published patent applications. Active years: 2026.
Years Active: 2026
Title: Benjamin Wigman: Innovator in Macrocyclic Compounds
Introduction
Benjamin Wigman is a notable inventor based in Woodland Hills, CA (US). He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of macrocyclic compounds. His work focuses on innovative methods for treating various forms of cancer.
Latest Patents
Wigman holds a patent for "Macrocyclic compounds and methods of use." This patent provides compounds that are useful for the inhibition of KRAS mutations, including G12D, G12V, G12A, G12S, G13D, Q61H, Q61L, or G12C. The compounds are described by a general Formula I′, with specific variables defined within the patent. Additionally, the disclosure includes pharmaceutical compositions that incorporate these compounds, highlighting their potential applications in cancer treatment.
Career Highlights
Throughout his career, Benjamin Wigman has demonstrated a commitment to advancing medical science through innovative research. His patent reflects a deep understanding of molecular biology and the complexities of cancer treatment. Wigman's work is a testament to the importance of innovation in the pharmaceutical industry.
Collaborations
Wigman has collaborated with notable colleagues, including Ryan Paul Wurz and Andrew Smaligo. These partnerships have likely contributed to the successful development of his patented compounds and their applications in cancer therapy.
Conclusion
Benjamin Wigman's contributions to the field of macrocyclic compounds represent a significant advancement in cancer treatment. His innovative approach and collaborative efforts underscore the importance of research and development in the pharmaceutical industry.